Breaking News Instant updates and real-time market news.

AVP

Avon Products

$2.09

0.07 (3.47%)

, ORCL

Oracle

$49.19

-0.06 (-0.12%)

09:15
09/18/18
09/18
09:15
09/18/18
09:15

Fly Intel: Pre-market Movers

HIGHER: Avon Products (AVP), up 6% after a report that Brazil's Natura Cosmeticos recently approached the company about a takeover... Viking Therapeutics (VKTX), up 121% after a Phase 2 study of VK2809 met its primary endpoint... Nutanix (NTNX), up 6% after William Blair analyst Jason Ader tells investors fears of Google (GOOGL) competition look overblown... Akcea Theraputics (AKCA), up 3% after a report that a group for patients suffering from the genetic condition familial chylomicronemia syndrome, or FCS, is circulating a petition asking the FDA to reconsider its decision to reject Akcea 's volanesorsen. DOWN AFTER EARNINGS: Oracle (ORCL), down 3.6%... FedEx (FDX), down 2%... AutoZone (AZO), down 5%... General Mills (GIS), down 1.5%. LOWER: Athenahealth (ATHN), down 9.5% after a report that Elliott Management has backed away from its $160 per share bid for the company... Madrigal Pharmaceuticals (MDGL), down 15% after the company's competitor Viking announced top-line results from a Phase 2 study of its novel liver-selective thyroid receptor beta agonist in patients with non-alcoholic fatty liver disease.

AVP

Avon Products

$2.09

0.07 (3.47%)

ORCL

Oracle

$49.19

-0.06 (-0.12%)

FDX

FedEx

$255.80

0.33 (0.13%)

VKTX

Viking Therapeutics

$10.40

-0.18 (-1.70%)

NTNX

Nutanix

$46.43

-6.07 (-11.56%)

AKCA

Akcea Therapeutics

$24.85

0.63 (2.60%)

AZO

AutoZone

$747.53

-1.44 (-0.19%)

GIS

General Mills

$47.77

0.04 (0.08%)

ATHN

Athenahealth

$143.26

-0.895 (-0.62%)

MDGL

Madrigal Pharmaceuticals

$228.67

2.77 (1.23%)

GOOG

Alphabet

$1,156.38

-15.515 (-1.32%)

GOOGL

Alphabet Class A

$1,159.33

-18.47 (-1.57%)

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 21

    Sep

  • 24

    Sep

  • 01

    Oct

  • 03

    Oct

  • 06

    Oct

  • 21

    Oct

  • 22

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Dec

  • 10

    Dec

  • 03

    Mar

AVP Avon Products
$2.09

0.07 (3.47%)

01/04/18
BOFA
01/04/18
DOWNGRADE
Target $2.5
BOFA
Underperform
Avon Products downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Avon Products to Underperform from Neutral and lowered its price target to $2.50 from $3.50. Analyst Olivia Tong does not expect a quick rebound for Avon in 2018 following underwhelming 2017 results and sees continued risk to sales, margins, and cash flow.
07/18/18
JEFF
07/18/18
UPGRADE
Target $1.5
JEFF
Hold
Avon Products upgraded to Hold from Underperform at Jefferies
Jefferies analyst Stephanie Wissink upgraded Avon Products to Hold while lowering her price target for the shares to $1.50 from $2. The analyst, who admits she has "limited confidence" in company's fundamentals and sees ongoing risk to sales drivers, believes shares of Avon are close to fair value. Wissink believes new management at Avon are exhibiting a "refreshing sense of urgency."
07/18/18
07/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comerica (CMA) upgraded to Outperform from In Line at Evercore ISI with analyst John Pancari saying he expects earnings growth to outpace peers while returns continue to strengthen, supported by a favorable positioning for higher short-term rates, ongoing efficiency improvement, and intact credit. 2. BorgWarner (BWA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Richard Kwas saying he sees limited share price downside risk and disproportionate upside potential from the current share price. 3. Avon Products (AVP) upgraded to Hold from Underperform at Jefferies with analyst Stephanie Wissink saying she believes shares of Avon are close to fair value. 4. Sunoco (SUN) upgraded to Hold from Underperform at Jefferies with analyst Christopher Sighinolfi saying while he still expects a 30% distribution cut and "equity needs" resulting from elevated leverage, he no longer sees "sufficient downside" with the shares down 10% since early April. 5. CSX (CSX) upgraded to Buy from Hold at Loop Capital with analyst Rick Paterson saying CSX is making "continued progress on the adoption of its scheduled operating model," delivering an operating ratio of 59.8% in Q2 vs. 64.7% last year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
01/04/18
BOFA
01/04/18
DOWNGRADE
BOFA
Underperform
Avon Products downgraded to Underperform from Neutral at BofA/Merrill
ORCL Oracle
$49.19

-0.06 (-0.12%)

09/18/18
LEHM
09/18/18
NO CHANGE
Target $60
LEHM
Overweight
Oracle shares look inexpensive after 'solid' Q1, says Barclays
Barclays analyst Raimo Lenschow views Oracle's Q1 results as "solid" but says the debate around the company will continue. With cloud and support revenue slightly below expectations and showing decelerating growth, the bears will continue to suspect support weakness and/or cloud deceleration, Lenschow tells investors in a post-earnings research note titled "Better Disclosure Would Help the Company." He believes the shares will likely be range bound with some support from Oracle's "aggressive" buyback program. This should last until the company delivers on its promised reacceleration in revenue, Lenschow contends. Nonetheless, he believes the shares look inexpensive and keeps an Overweight rating on Oracle with a $60 price target.
09/18/18
WEDB
09/18/18
NO CHANGE
Target $49
WEDB
Neutral
'Not much in the way' of positive catalysts at Oracle, says Wedbush
Wedbush analyst Steve Koenig maintained a Neutral rating and $49 price target on Oracle following the company's Q1 results, telling investors in a research note that Q1 software revenue growth of 3% "probably won't impress investors." His checks suggest that NetSuite and Financials Cloud are doing best among Oracle's cloud portfolio, but that overall cloud renewal rates remain well below industry norms and says the company's key challenge will be to figure out how to capitalize on and monetize on customers' shift to the cloud with Oracle's database offering. He also lacks confidence that the company can make significant IaaS inroads into its database customer base or stem the rising tide of AWS (AMZN) in Oracle's enterprise market and doesn't see much in the way of positive catalysts.
09/18/18
OPCO
09/18/18
NO CHANGE
OPCO
Perform
Oracle's business 'off to a slow start' in Q1, says Oppenheimer
Oppenheimer analyst Brian Schwartz maintained a Perform rating on Oracle following the company's "soft" Q1 results and below consensus Q2 guidance. In a research note to investors, Schwartz says Oracle's business "got off to a slow start" in Q1, and cautions investors getting involved in "bottom fishing" Oracle shares in the hopes of outsized returns. He says Oracle's cloud transition has come "too late," resulting in steady customer and workload attrition to competitors, and says that the business remains under pressure and guidance suggests large company M&A and the corresponding risks "are near."
09/18/18
RBCM
09/18/18
NO CHANGE
Target $53
RBCM
Sector Perform
Oracle price target raised to $53 at RBC Capital after Q1 earnings
RBC Capital analyst Ross MacMillan nudged his price target on Oracle to $53 from $52 after its "broadly in-line" Q1 results, saying the earnings upside was driven by the lower tax rates and buybacks even though the outlook for Q2 was below expectations. MacMillan keeps his Sector Perform rating on the shares, stating that he sees no "meaningful case for multiple expansion" based on his expectations of declining growth rates and shrinking gross margins. The analyst further notes that Oracle's transition to a "cloud-centric world" has been "uneven" with a shrinking on-premise license business, adding that at current prices, risk-reward on the shares is "balanced".
FDX FedEx
$255.80

0.33 (0.13%)

09/18/18
MSCO
09/18/18
NO CHANGE
Target $242
MSCO
Equal Weight
FedEx's 'big miss' in Q1 raises stakes for rest of year, says Morgan Stanley
Morgan Stanley analyst Ravi Shanker said FedEx's "big miss" in Q1 EPS was not purely cost-driven, as weaker pricing drove a revenue miss compared to his expectations. Despite the Q1 miss, FedEx raised its full-year EPS guidance due to "rounding," but Shanker sees pressure on the coming quarters' results and said the Q1 report raises the stakes for the remainder of the year. He lowered his price target on FedEx shares to $242 from $245 following the report and keeps an Equal Weight rating on the stock.
09/18/18
FBCO
09/18/18
NO CHANGE
Target $307
FBCO
Outperform
FedEx price target cut to $307 from $315 at Credit Suisse
Credit Suisse analyst Allison Landry maintained an Outperform rating on FedEx but cut her price target to $307 from $315 following the company's weaker Q1 operating results. In a research note to investors, Landry says that although expectations "weren't high," the Q1 EBIT shortfall and the "low-quality" FY guidance should be enough to be met with a negative reaction from investors, but expects "modest" pressure on the stock today as FY top line and EBIT margins were reiterated. Landry says she "wasn't thrilled" with the results, but thinks there is merit to what CEO Fred Smith pointed out that quarterly earnings don't tell the whole story.
09/18/18
COWN
09/18/18
NO CHANGE
Target $280
COWN
Outperform
FedEx weakness a buying opportunity, says Cowen
Cowen analyst Helane Becker noted FedEx shares were weak in the aftermarket following Q1 earnings that were below expectations. The analyst said she would use the weakness as a buying opportunity as management raised the full-year earnings range due to a strong economy and continued traction with revenue and cost initiatives. Becker reiterated her Outperform rating and $280 price target on FedEx shares.
09/18/18
OPCO
09/18/18
NO CHANGE
Target $288
OPCO
Outperform
Oppenheimer says 'buy the dip' at FedEx following 'mixed' Q1 results
Oppenheimer analyst Scott Schneeburger maintained an Outperform rating and $288 price target on FedEx following the company's "mixed" quarterly results, telling investors in a research note to "buy the dip." Despite the softer start, FedEx maintained its FY19 revenue growth guidance and increased its adjusted EPS range and Schneeburger anticipates a strong peak season and broad-based second half of 2019-2020 lift.
VKTX Viking Therapeutics
$10.40

-0.18 (-1.70%)

07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
06/28/18
RAJA
06/28/18
INITIATION
Target $15
RAJA
Outperform
Viking Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated Viking Therapeutics with an Outperform and $15 price target.
07/20/18
07/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. OneMain Holdings (OMF) reinstated with an Equal Weight at Barclays. 2. Viking Therapeutics (VKTX) initiated with a Buy at SunTrust. 3. Semtech (SMTC) initiated with a Buy at Stifel. 4. Axon (AAXN) initiated with a Buy at Needham. 5. Sonoma Pharmaceuticals (SNOA) assumed with a Speculative Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/18
RHCO
07/20/18
INITIATION
Target $14
RHCO
Buy
Viking Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Viking Therapeutics with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non- alcoholic steatohepatitis disease, or NASH. The analyst adds that VK2809 demonstrated a significant reduction in multiple lipid parameters in phase 1b trials, and also notes that the stock is trading at a significant discount relative to other companies targeting NASH.
NTNX Nutanix
$46.43

-6.07 (-11.56%)

08/31/18
JMPS
08/31/18
NO CHANGE
Target $60
JMPS
Outperform
Nutanix increased spending prudent, says JMP Securities
JMP Securities analyst Erik Suppiger noted that Nutanix shares traded down 6% in the afterhours following its Q4 report, which he attributes to guidance that reflects continued top-line momentum but higher expenses as the company invests in both sales and products. He thinks the increased spending is prudent given the company's large market opportunity and sees the strength in billings, driven by strong performance in large accounts, continuing to fuel growth. Suppiger maintain his Outperform rating and $60 price target on Nutanix shares, which he continues to view as undervalued.
08/31/18
KEYB
08/31/18
NO CHANGE
Target $68
KEYB
Overweight
KeyBanc remains buyer of Nutanix after 'strong' Q4 results
KeyBanc analyst Alex Kurtz says Nutanix last night delivered "solid" software and support billings up 66% year-over-year, driven by ongoing large deal strength and growth in Global 2000 repeat purchases. He attributes the post-earnings pullback to the company's "aggressive" spending model and the lower Q1 revenue guidance due to a faster transition from hardware revenue. The analyst, however, views the Q4 print as "strong" and remains a buyer of the shares with an Overweight rating and $68 price target.
09/18/18
PIPR
09/18/18
NO CHANGE
Target $66
PIPR
Overweight
Piper calls Nutanix selloff on Google competition concerns 'excessive'
Nutanix (NTNX) shares dropped 11.5% yesterday due to an article from The Information citing a potential competitive hyperconverged infrastructure offering from Google (GOOG, GOOGL), Piper Jaffray analyst Andrew Nowinski tells investors in a research note. According to the article, Google is building custom-designed hyperconverged infrastructure solutions for a handful of large customers that will run inside these customers' private datacenters. While the potential offering could be viewed as competitive to Nutanix, most enterprises will choose to leverage a multi-cloud infrastructure and would not want to be locked into single cloud provider, Nowinski contends. As such, the analyst views yesterday's selling pressure as "excessive" and reiterates an Overweight rating on Nutanix with a $66 price target. The stock closed yesterday down $6.07 to $46.47.
09/18/18
WBLR
09/18/18
NO CHANGE
WBLR
Outperform
Fears of Google competition for Nutanix look overblown, says William Blair
Shares of Nutanix (NTNX) fell yesterday after The Information reported that Google (GOOG, GOOGL) is working on a potential hyperconverged infrastructure product that could conceptually compete with Nutanix, William Blair analyst Jason Ader tells investors in a research note titled "Fears of Google Entering HCI Space Look Overblown to Us". This is likely Google's response to what Microsoft (MSFT) has built with Azure Stack, which is Microsoft's HCI product that connects directly into its Azure public cloud service, Ader contends. He believes that if Google turn this into an actual packaged HCI product sold to a broad range of customers, it could create longer-term risk for Nutanix. However, thinks investors should consider that this appears to be another validation of the staying power of the on-premises market, which he says bodes well for Nutanix. Further, he points out that if Google were to decide to enter the HCI market more broadly, it would have a long way to go to establish itself in the enterprise against entrenched players like Nutanix and VMware (VMW). Google has not had great success selling into the enterprise historically and has little experience selling enterprise infrastructure appliances, Ader writes. The analyst reiterates an Outperform rating on Nutanix.
AKCA Akcea Therapeutics
$24.85

0.63 (2.60%)

08/28/18
HCWC
08/28/18
NO CHANGE
HCWC
Neutral
Ionis CRL for Waylivra raises questions on Tegsedi approval, says JPMorgan
Ionis Pharmaceuticals (IONS) announced last night that its subsidiary Akcea Therapeutics (AKCA) received a complete response letter for Waylivra from the FDA. JPMorgan analyst Jessica Fye says she had a chance to catch up with management but that they did not provide much in the way of details regarding the CRL. Given that Waylivra and Tegsedi are both generation 2.5 products and both have had platelet safety issues, the market will naturally question if the risk of a CRL also extends to Tegsedi, Fye tells investors in a research note. The analyst expects Ionis shares to reflect greater risk to approval for Tegsedi as well as Waylivra. She notes that Waylivra is worth $2 per share in her model for Ionis while Tegsedi contributes greater than $10 per share. The stock in premarket trading is down 12%, or $6.68, to $47.02. Fye keeps a Neutral rating on Ionis Pharmaceuticals.
08/28/18
RILY
08/28/18
NO CHANGE
Target $230
RILY
Buy
Ionis CRL positive for Alnylam's Onpattro, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar believes the complete response letter for Ionis Pharmaceuticals' (IONS) and Akcea Therapeutics' (AKCA) Waylivra is positive for Alnylam Pharmaceuticals' (ALNY) Onpattro. The analyst reiterates a Buy rating on Alnylam with a $230 price target.
08/28/18
STFL
08/28/18
NO CHANGE
STFL
Hold
CRL for Waylivra 'somewhat of a surprise,' says Stifel
Stifel analyst Paul Matteis said the complete response letter for Ionis Pharmaceuticals (IONS) and Akcea Therapeutics' (AKCA) Waylivra was "somewhat of a surprise" given the positive advisory committee decision, though he also noted that "safety was acutely in focus" during the committee meeting. The basis of the CRL is not yet known and Akcea was "close to the vest" on its nature, leading Matteis to remove Waylivra from his valuations for the two stocks. Doing that lowered his Akcea price target to $25 from $33 and cut his Ionis target to $45 from $47. However, he thinks the main investor question will be regarding read-through to Tegsedi and Matteis' assumption for its approval remains unchanged, he added. The analyst keeps Hold ratings on Ionis and Akcea shares, which are down 12.5% and 29%, respectively, in pre-market trading.
09/18/18
NEED
09/18/18
INITIATION
Target $45
NEED
Buy
Akcea Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Akcea Therapeutics (AKCA) with a Buy rating and a price target of $45, saying it is an "attractive" way for investors to leverage "decades of innovation" by the parent Ionis Pharma (IONS) through ownership of its most advanced-stage programs. The analyst cites the unfolding "breakthrough" in the approval of a new class of antisense drugs which "directly block protein synthesis in cells by binding to RNA". Messer adds that Akcea is positioned for near-term commercial opportunity for its Tegsedi and Waylivra programs.
AZO AutoZone
$747.53

-1.44 (-0.19%)

08/30/18
ARGS
08/30/18
NO CHANGE
Target $820
ARGS
Buy
AutoZone price target lowered to $820 from $850 at Argus
Argus analyst Deborah Ciervo lowered her price target on AutoZone (AZO) to $820, saying the stock price gains have been constrained by the possibility of competition from Amazon (AMZN) given the company's relatively larger exposure to the DIY vs. commercial market. The analyst also keeps her Buy rating, citing expectations of continued "solid industry fundamentals", citing the industry trends of aging fleet of autos, low gas prices, and increasing per-car total miles. The analyst raises her FY18 EPS view to $49.98 from $49.24 to reflect the positive impact of lower tax rates and reduced cost of goods sold.
09/17/18
BOFA
09/17/18
DOWNGRADE
BOFA
Neutral
AutoZone downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Elizabeth Suzuki downgraded AutoZone to Neutral from Buy with a $830 price target due to overexposure to the DIY segment and competition. Suzuhi believes AutoZone may experience a slowdown in comps while competitors experience an acceleration.
09/12/18
DBAB
09/12/18
NO CHANGE
Target $805
DBAB
Buy
Deutsche positive on AutoZone ahead of next week's earnings report
Deutsche Bank analyst Mike Baker sees "several reasons" for upside to the consensus comp forecast into AutoZone's Q4 results on September 18. The analyst is modeling comps to be up 3.1% compared to consensus of 2.4%. He sees favorable industry trends, some early signs that inflation should help comps, and help from cycling Hurricane Harvey at the end of the quarter. This, along with favorable gross margin trends, "well telegraphed" expense increases and a "below average" valuation leaves Baker positive on AutoZone shares into the print. He keeps a Buy rating on the name with an $805 price target.
09/13/18
WELS
09/13/18
NO CHANGE
Target $850
WELS
Outperform
AutoZone price target raised to $850 from $800 at Wells Fargo
Wells Fargo analyst Zachary Fadem raised his price target for AutoZone to $850 from $800 as he remains constructive on AutoZone into Q4, with positive industry read-throughs, manageable expectations, and plenty of room for valuation catch up versus peers. The analyst reiterates an Outperform rating on the shares.
GIS General Mills
$47.77

0.04 (0.08%)

09/17/18
09/17/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. LULULEMON UPGRADED TO OUTPERFORM: Wells Fargo analyst Ike Boruchow upgraded Lululemon (LULU) to Outperform from Market Perform, stating that while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. While admitting to being "late to the party," Boruchow said he sees meaningful outperformance and upward revisions being ahead for the athletic apparel company. He raised his price target on Lululemon shares to $200 from $144. In late morning trading, Lululemon shares are higher by 2.3%. NOMURA UPGRADES BROADCOM TO BUY: Nomura Instinet analyst Romit Shah upgraded Broadcom (AVGO) to Buy from Neutral and raised his price target for the shares to $300 from $225. The analyst says the "so many positive takeaways from earnings" have forced him to take a more constructive stance on the shares. GOLDMAN SWAPS CONVICTION BUY ON MASTERCARD, VISA: Goldman Sachs analyst James Schneider added MasterCard (MA) to his firm's Conviction List while maintaining a Buy rating on the shares. The analyst also upped his price target for the stock to $260 from $230. Goldman Sachs analyst James Schneider removed Visa (V) from his firm's Conviction List but maintains a Buy rating on the shares with an unchanged price target of $160. The analyst, who continues to see upside to Street estimates, cites the recent share outperformance for the removal. MORGAN STANLEY INITIATES CONSUMER STAPLES: Morgan Stanley analyst Dara Mohsenian assumed Kraft Heinz (KHC) with an Underweight and $52 price target, as he believes it topline growth will likely trail food peers. In late morning trading, Kraft Heinz shares were down almost 2%. The analyst also assumed coverage of Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) with Equal Weight ratings. KEYBANC SEES CANNABIS AS DRIVER FOR SHOPIFY: KeyBanc analyst Monika Garb said she is a buyer of Shopify (SHOP), as the company has "ample" growth opportunities ahead, and she sees potential upside to her above-consensus estimates. She expects that recreational sales of cannabis in Canada could be a GMV and revenue driver and further benefit Shopify's business momentum. Garb maintained an Overweight rating and $182 price target on the shares.
09/17/18
09/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Reliance Steel (RS) initiated with a Neutral at Citi. 2. Bausch Health (BHC) assumed with an Overweight at Barclays. 3. Stanley Black & Decker (SWK) initiated with an Outperform at Credit Suisse. 4. Aramark (ARMK) initiated with an Outperform at Bernstein. 5. Kraft Heinz (KHC) was assumed with an Underweight at Morgan Stanley, while Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) were assumed with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
RBCM
09/17/18
NO CHANGE
Target $52
RBCM
Sector Perform
General Mills price target raised to $52 at RBC Capital on more stable trends
RBC Capital analyst David Palmer nudged his price target on General Mills to $52 from $50 and kept his Sector Perform rating, saying that while the company's sales trends have not accelerated as much as its peers, they have been more stable and relied less on promotional activity. The analyst notes that the company faces a more challenging cereal comparison ahead, but also offers investors a "compelling free cash flow" and has some further sources of upside such as distribution gains for Blue Buffalo along with the recent wins like gains in yogurt category. Palmer also nudged his FY19 EPS view on General Mills to $3.06 from $3.04.
09/17/18
MSCO
09/17/18
INITIATION
Target $47
MSCO
Equal Weight
Mondelez assumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian assumed coverage of Mondelez (MDLZ) with an Equal Weight rating and $47 price target, calling it the best positioned among the large cap food peers on which he began coverage. However, Mohsenian assumed the U.S. large-cap packaged food industry with an In-Line rating, stating that he is cautious fundamentally given his skepticism over packaged food sector topline growth and margin expansion potential. Mohsenian also assumed coverage of General Mills (GIS) and Kellogg (K) with Equal Weight ratings and assumed Kraft Heinz (KHC) with an Underweight rating.
ATHN Athenahealth
$143.26

-0.895 (-0.62%)

07/31/18
PIPR
07/31/18
NO CHANGE
Target $179
PIPR
Overweight
Athenahealth Q2 shows 'resiliency of the model,' says Piper Jaffray
Piper Jaffray analyst Sean Wieland says Athenahealth's Q2 results "demonstrate the resiliency of the model" in the wake of the CEO's exit. The analyst is encouraged by the strength of the core ambulatory business and the company's investments in innovation. He views Elliot's $160 per share offer as "downside" and thinks the business should fetch more upon completion of the strategic review. Wieland reiterates an Overweight rating on Athenahealth with a $179 price target.
08/10/18
CANT
08/10/18
NO CHANGE
Target $300
CANT
Overweight
Cantor sees 'many reasons' for UnitedHealth acquiring Athenahealth
Numerous media sources yesterday cited a Dealreporter story indicating that UnitedHealth (UNH) is now in the second round of bidding for Athenahealth (ATHN), Cantor Fitzgerald analyst Steven Halper tells investors in a research note partially titled "It's Crazy but Not So Crazy." There are "many reasons" why UnitedHealth's Optum would benefit from the acquisition of Athenahealth, the analyst contends. He points out that Optum has a large presence in the Boston area and that Athenahealth is located principally in Watertown, Massachusetts. Further, UnitedHealth "can certainly afford" the deal given its strong balance sheet and cash flow, Halper adds. With or without the deal, the analyst expects UnitedHealth will deploy capital and grow its various Optum businesses over time. He reiterates an Overweight rating on the shares with a $300 price target.
08/16/18
CANT
08/16/18
NO CHANGE
CANT
Overweight
Cantor Fitzgerald backs 'positive' view of healthcare IT segment
Cantor Fitzgerald Steven Halper tells investors in a research note that he is maintaining a positive investment view of the healthcare IT segment, and believes demand for products and services in the sector will continue to drive long-term growth. Specifically, he continues to rate Cerner (CERN) and Evolent Health (EVH) Overweight, as both are "nicely" leveraged to population health, with Evolent mostly a pure play in the segment. Within managed care, Halper believes Overweight-rated UnitedHealth (UNH) remains well-positioned with its Optum segment.
08/10/18
08/10/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN CUTS INTEL, UPGRADES AMD: Goldman Sachs analyst Toshiya Hari downgraded Intel (INTC) to Sell from Neutral and lowered his price target for the shares to $44 from $49. Hari coupled the downgrade with an upgrade of AMD (AMD) to Neutral from Sell. Intel's struggles with 10nm process technology made the analyst incrementally more negative on the company's competitive positioning and margin outlook. He expects a worsening product mix in the near-term, ramp in 10nm costs and growing depreciation to drive margin pressure and Intel's earnings below consensus expectations. The delay in Intel's new products will allow AMD to gain share in not only client computer processing units, and also in the "lucrative" server CPU market, Hari contended. He believes this makes for a balanced risk/reward profile on AMD shares. In late morning trading, Intel is down 2.5% and AMD is up fractionally. BOOKING HOLDINGS DOWNGRADED AT MULTIPLE FIRMS: UBS analyst Eric Sheridan downgraded Booking Holdings (BKNG) to Neutral from Buy and lowered his price target for the shares to $2,060 from $2,320 following the company's Q2 results. JPMorgan analyst Doug Anmuth downgraded Booking Holdings to Neutral from Overweight and lowered his price target for the shares to $2,070 from $2,385. Additionally, Citi analyst Mark May downgraded Booking Holdings to Neutral from Buy and lowered his price target for the shares to $2,150 from $2,350. Booking Holding is down over 2% in late morning trading. JPMORGAN CUTS CAMPBELL SOUP TO UNDERWEIGHT: JPMorgan analyst Ken Goldman downgraded Campbell Soup (CPB) to Underweight from Neutral with a $36 price target, saying he believes a sale of the company at a significant premium is unlikely. Campbell Soup is down over 2% in late morning trading. CANTOR SEES MANY REASONS FOR UNITEDHEALTH ACQUIRING ATHENAHEALTH: Numerous media sources cited a Dealreporter story indicating that UnitedHealth (UNH) is now in the second round of bidding for Athenahealth (ATHN), Cantor Fitzgerald analyst Steven Halper said in a research note. There are "many reasons" why UnitedHealth's Optum would benefit from the acquisition of Athenahealth, the analyst contended. With or without the deal, the analyst expects UnitedHealth will deploy capital and grow its various Optum businesses over time. He reiterated an Overweight rating on shares with a $300 price target.
MDGL Madrigal Pharmaceuticals
$228.67

2.77 (1.23%)

09/04/18
SBSH
09/04/18
INITIATION
Target $340
SBSH
Buy
Madrigal Pharmaceuticals initiated with a Buy at Citi
Citi analyst Joel Beatty started Madrigal Pharmaceuticals with a Buy rating and $340 price target. The company's MGL-3196 appears to be the favorite among four non-alcoholic steatohepatitis drugs in late stage development, Beatty tells investors in a research note. The analyst models $3.5B in 2026 sales for MGL-3196 in NASH, and a 65% probability-adjusted likelihood of approval.
08/06/18
GSCO
08/06/18
DOWNGRADE
Target $314
GSCO
Neutral
Madrigal Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Madrigal Pharmaceuticals to Neutral with an unchanged price target of $314. The stock closed Friday down 41c to $250.93. The analyst continues to view MGL-3196 as a "best-in-industry, next-generation drug" for nonalcoholic steatohepatitis. However, with the stock up 173% year-to-date, he believes Madrigal is entering a "period of limited value-driving catalysts." Richter, while admitting a buyout could occur, sees limited upside in the shares.
07/12/18
CANT
07/12/18
INITIATION
Target $59
CANT
Overweight
Cantor puts $59 price target on 'undervalued' NASH play Galmed
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target. The stock closed yesterday down 45c to $10.55. The company is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fattyacid/bile-acid conjugates, Piros tells investors in a research note. The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol. Of the three drugs, Galmed's has the highest likelihood of achieving improvement on NASH resolution without worsening of fibrosis, and improvement in fibrosis score without worsening of NASH, Piros argues. He believes Galmed is undervalued relative to peers in the NASH space.
08/06/18
GSCO
08/06/18
UPGRADE
Target $157
GSCO
Buy
Intercept upgraded to Buy from Sell at Goldman Sachs
Goldman Sachs analyst Salveen Richter double upgraded Intercept Pharmaceuticals (ICPT) to Buy from Sell and raised his price target for the shares to $157 from $46. The stock closed Friday down 3.5%, or $3.57, to $97.26. The analyst says Ocaliva in fatty liver disease nonalcoholic steatohepatitis is the crux of Intercept's value proposition and that he's positive into the Phase 3 Regenerate interim readout in the first half of 2019. Richter this morning also downgraded Madrigal Pharmaceuticals (MDGL) to Neutral from Buy. He believes, however, that Madrigal's MGL-3196 is a "best-in-industry, next-generation" drug for nonalcoholic steatohepatitis. The analyst expects Intercept's Ocaliva will achieve one or both of the Phase 3 co-primary endpoints of NASH resolution and fibrosis improvement. He sees share upside of 60%-plus as the first half of 2019 catalyst approaches. Intercept should benefit from Ocaliva's global first-mover advantage in NASH, Richter tells investors in a research note. Goldman estimates peak global sales of NASH drugs to be $3.7B.
GOOG Alphabet
$1,156.38

-15.515 (-1.32%)

09/14/18
PIPR
09/14/18
NO CHANGE
PIPR
Piper says Amazon, Facebook, Alphabet attractive despite regulatory pressure
Piper Jaffray analyst Michael Olson believes shares of Amazon.com (AMZN), Facebook (FB) and Alphabet (GOOG, GOOGL) remain attractive despite increased regulatory pressure in the near-term. While current regulatory challenges present "multiple issues over the next few months," the long-term outlook remains favorable for all three companies, Olson tells investors in a research note. The analyst believes Facebook may be becoming less exposed from a regulatory perspective going forward given that the company "has now done extensive work to bring its platform in line with recent privacy regulations and because it is now giving the deserved attention to privacy." Between the three companies, Alphabet may face the most regulatory headwind given its open infrastructure marketing platform exposure on privacy and targeting, susceptibility to copyright changes through YouTube, and its dominant position in search amenable to antitrust issues, the analyst contends. However, he believes Google, YouTube, Android, and Gmail together "create a once-in-a-generation asset with continued strong revenue growth potential, high margins, and secular tailwinds." For Amazon, Olson sees the biggest worries as antitrust and Post Office changes. However, he thinks antitrust law precedent will be upheld and points out the company continues to build its own last-mile delivery to lessen its dependency on the United States Postal Service.
09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.
GOOGL Alphabet Class A
$1,159.33

-18.47 (-1.57%)

09/13/18
CLVD
09/13/18
NO CHANGE
CLVD
Buy
Cleveland Research lowers Facebook Q3 sales growth estimate
Cleveland Research analyst Chandler Converse said feedback on near-term Facebook ad spending has turned more cautious as a result of changes to limit targeting and tracking in response to increased scrutiny and regulation. The targeting and tracking changes are viewed as driving lower ROI for some advertisers, leading to reduced budget allocation, while Facebook also appears to be seeing increased competitive pressure from Google (GOOGL) and Amazon (AMZN), Converse tells investors. The analyst lowered his Q3 sales growth forecast to about 33% from a prior view of 35%, though he maintains a Buy rating on Facebook shares.
09/12/18
SBSH
09/12/18
NO CHANGE
SBSH
Amazon remains Citi's top pick in U.S. Internet
Citi analyst Mark May keeps Amazon.com (AMZN) as his top pick in U.S. Internet based on recent data points pertaining to company fundamentals, the near-term setup, recent stock performance, investor sentiment and changes since his last update. Alphabet (GOOG, GOOGL), Yelp (YELP), Expedia (EXPE), GrubHub (GRUB) and GoDaddy (GDDY) moved up in his rankings while Facebook (FB), eBay (EBAY), Twitter (TWTR), TripAdvisor (TRIP) and Booking Holdings (BKNG) moved down.

TODAY'S FREE FLY STORIES

03:40
10/19/18
10/19
03:40
10/19/18
03:40
General news
FX Action: USD-CAD printed a near six-week high »

FX Action: USD-CAD…

02:35
10/19/18
10/19
02:35
10/19/18
02:35
General news
FX Update: The Dollar has held firm against most currencies »

FX Update: The Dollar…

01:40
10/19/18
10/19
01:40
10/19/18
01:40
General news
Asian Market Wrap: »

Asian Market Wrap:…

22:20
10/18/18
10/18
22:20
10/18/18
22:20
General news
China's GDP slowed to a 6.5% y/y growth pace in Q3 »

China's GDP slowed…

NI

NiSource

$25.25

0.22 (0.88%)

21:12
10/18/18
10/18
21:12
10/18/18
21:12
Downgrade
NiSource rating change at Goldman Sachs »

NiSource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PNW

Pinnacle West

$83.48

-0.235 (-0.28%)

21:04
10/18/18
10/18
21:04
10/18/18
21:04
Upgrade
Pinnacle West rating change at Goldman Sachs »

Pinnacle West upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

NVS

Novartis

$86.24

0.9 (1.05%)

20:26
10/18/18
10/18
20:26
10/18/18
20:26
Hot Stocks
Novartis granted orphan status for melanoma treatment »

The FDA granted Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

, HON

Honeywell

$155.22

-2.73 (-1.73%)

20:25
10/18/18
10/18
20:25
10/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

HON

Honeywell

$155.22

-2.73 (-1.73%)

SLB

Schlumberger

$58.43

-0.81 (-1.37%)

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

STT

State Street

$79.62

-2.5 (-3.04%)

STI

SunTrust

$61.46

-0.94 (-1.51%)

SYF

Synchrony

$29.63

-0.45 (-1.50%)

CFG

Citizens Financial

$34.92

-0.96 (-2.68%)

KSU

Kansas City Southern

$102.68

-1.31 (-1.26%)

IPG

Interpublic Group

$22.48

0.28 (1.26%)

EEFT

Euronet

$112.64

-2.96 (-2.56%)

MAN

Manpower

$78.38

-1.09 (-1.37%)

GNTX

Gentex

$18.62

-0.32 (-1.69%)

CLF

Cleveland-Cliffs

$11.47

-0.37 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 26

    Nov

  • 26

    Nov

  • 06

    Dec

  • 03

    Mar

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

20:24
10/18/18
10/18
20:24
10/18/18
20:24
Upgrade
Canadian Pacific rating change at National Bank »

Canadian Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

19:57
10/18/18
10/18
19:57
10/18/18
19:57
Hot Stocks
DowDuPont clarifies the charge is the result of previously reported conditions »

In response to market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

19:35
10/18/18
10/18
19:35
10/18/18
19:35
Downgrade
Valero Energy Partners rating change at RBC Capital »

Valero Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

IVZ

Invesco

$21.26

0.32 (1.53%)

19:33
10/18/18
10/18
19:33
10/18/18
19:33
Downgrade
Invesco rating change at Credit Suisse »

Invesco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

LOGC

LogicBio Therapeutics

$0.00

(0.00%)

19:31
10/18/18
10/18
19:31
10/18/18
19:31
Syndicate
LogicBio Therapeutics 7M share IPO priced at $10.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MDSO

Medidata

$70.91

1.54 (2.22%)

19:07
10/18/18
10/18
19:07
10/18/18
19:07
Recommendations
Medidata analyst commentary at JPMorgan »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$263.85

-8.09 (-2.97%)

18:58
10/18/18
10/18
18:58
10/18/18
18:58
Periodicals
Tesla rolls out new Model 3 with 'mid-range' battery pack, Electrek reports »

Tesla today is rolling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Dec

SKX

Skechers

$26.05

-0.64 (-2.40%)

, PYPL

PayPal

$77.50

-2.61 (-3.26%)

18:51
10/18/18
10/18
18:51
10/18/18
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$26.05

-0.64 (-2.40%)

PYPL

PayPal

$77.50

-2.61 (-3.26%)

CE

Celanese

$97.01

-2.76 (-2.77%)

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

ISRG

Intuitive Surgical

$522.41

-20.44 (-3.77%)

AXP

American Express

$102.86

-1.53 (-1.47%)

ETFC

E-Trade

$48.89

-1.68 (-3.32%)

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

VLO

Valero

$103.31

-0.36 (-0.35%)

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

OZK

Bank OZK

$34.85

-1.57 (-4.31%)

LLNW

Limelight Networks

$5.07

0.12 (2.42%)

TEAM

Atlassian

$81.96

-1.67 (-2.00%)

AIG

AIG

$48.62

-0.99 (-2.00%)

SREV

ServiceSource

$2.60

-0.08 (-2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 29

    Oct

  • 05

    Nov

  • 07

    Nov

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 05

    Dec

  • 06

    Dec

X

U.S. Steel

$27.91

-0.27 (-0.96%)

, AKS

AK Steel

$4.69

-0.115 (-2.39%)

18:47
10/18/18
10/18
18:47
10/18/18
18:47
Periodicals
U.S. requests WTO panel to examine metals tariffs retaliation, Reuters says »

The U.S. has asked the…

X

U.S. Steel

$27.91

-0.27 (-0.96%)

AKS

AK Steel

$4.69

-0.115 (-2.39%)

NUE

Nucor

$58.26

-0.85 (-1.44%)

STLD

Steel Dynamics

$41.32

0.77 (1.90%)

AA

Alcoa

$38.85

2.14 (5.83%)

CENX

Century Aluminum

$9.91

-0.23 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 25

    Oct

  • 26

    Oct

  • 02

    Nov

RLH

Red Lion Hotels

$12.62

-0.42 (-3.22%)

18:43
10/18/18
10/18
18:43
10/18/18
18:43
Hot Stocks
Red Lion Hotels CFO Douglas Ludwig resigns due to personal health reasons »

RLH Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

IDA

IDACORP

$96.78

0.035 (0.04%)

18:30
10/18/18
10/18
18:30
10/18/18
18:30
Hot Stocks
IDACORP declares quarterly dividend of 63c per share »

Director of IDACORP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$20.70

-0.59 (-2.77%)

18:08
10/18/18
10/18
18:08
10/18/18
18:08
Syndicate
Krystal Biotech 3M share Secondary priced at $20.00 per share »

Cowen, William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

, SVU

Supervalu

$32.49

0.02 (0.06%)

18:05
10/18/18
10/18
18:05
10/18/18
18:05
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

SVU

Supervalu

$32.49

0.02 (0.06%)

UNFI

United Natural Foods

$26.94

0.2 (0.75%)

TTGT

TechTarget

$19.53

-0.35 (-1.76%)

PERY

Perry Ellis

$27.48

0.02 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 28

    Oct

  • 07

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

SXT

Sensient

$76.67

-1.15 (-1.48%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
Sensient raises quarterly dividend to 36c from 33c per share »

The cash dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
DowDuPont says Sept. quarter results won't be impacted by $4.5B goodwill charge »

On October 18, 2018, E.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$3.54

-0.13 (-3.54%)

17:55
10/18/18
10/18
17:55
10/18/18
17:55
Hot Stocks
Northern Oil and Gas sees Q4 production 58% greater than Q2 »

Liquidity has increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SHPG

Shire

$176.90

-0.4 (-0.23%)

17:47
10/18/18
10/18
17:47
10/18/18
17:47
Hot Stocks
FDA advisory committee recommends Shire's Prucalopride for CIC »

Shire announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 21

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.